斯托克治疗

最新新闻

• 评级变动
  TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/2/11
• 评级变动
  CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)
  TipRanks · 2026/8/4
• A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/4/22
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Genelux Corp. (GNLX) and Celldex (CLDX)
  TipRanks · 2026/5/9
• 评级变动
  Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• 评级变动
  Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60
  \u5e02\u573a\u8d44\u8baf · 2026/5/9
• 评级变动
  Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/3/18
• 评级变动
  Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/3/17
• 评级变动
  Guggenheim Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/2/5
• CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Wolfe Research Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/3/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。